Cancer Invest

• 

  Publication Venue For

  • Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma..  39:871-879. 2021
  • Targeting MET Amplification with Crizotinib in a Case of Sinonasal Undifferentiated Carcinoma..  39:235-239. 2021
  • Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer..  35:333-344. 2017
  • Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer..  35:32-35. 2017
  • Quality of Life is Similar between Long-term Survivors of Indolent and Aggressive Non-Hodgkin Lymphoma..  34:279-285. 2016
  • Patient-Centered Communication for Discussing Oncotype DX Testing..  34:205-212. 2016
  • Tumor acquisition for biomarker research in lung cancer..  32:291-298. 2014
  • Endothelial colony forming cells (ECFCs) as a model for studying effects of low-dose ionizing radiation: growth inhibition by a single dose..  31:359-364. 2013
  • A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma..  31:172-176. 2013
  • Statement of retraction: Hongying Lv, Qicai Li, Wengsheng Qiu, Jinyu Xiang, Hongjun Wei, Hua Liang, Aihua Sui and Jun Liang "Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer"..  31:661-. 2013
  • Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry..  30:679-682. 2012
  • The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost..  30:637-641. 2012
  • Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature..  30:1-12. 2012
  • A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer..  29:617-625. 2011
  • New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response..  29:533-541. 2011
  • The genomic relationship between primary breast carcinomas and their nodal metastases..  29:300-307. 2011
  • Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors..  29:56-61. 2011
  • Thrombin expression in prostate: a novel finding..  29:62-67. 2011
  • A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer..  28:978-982. 2010
  • The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features..  28:969-977. 2010
  • Immune signatures predict prognosis in localized cancer..  28:765-773. 2010
  • Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy..  28:654-660. 2010
  • Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy..  28:554-559. 2010
  • Anthracyclines in the treatment of early-stage breast cancer: ally or adversary?.  28:217-219. 2010
  • Breast cancer screening: science, society and common sense..  28:1-6. 2010
  • Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer..  27:953-959. 2009
  • Gene expression profile assays as predictors of distant recurrence-free survival in early-stage breast cancer..  27:885-890. 2009
  • Comparative effectiveness research in oncology: the need for clarity, transparency and vision..  27:593-597. 2009
  • Cancer and thrombosis: back to the future renewed interest in an old problem..  27:472-473. 2009
  • Primary systemic therapy in breast cancer: past lessons and new approaches..  26:1052-1059. 2008
  • Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors..  26:794-799. 2008
  • Induction of the human heat shock promoter HSP70B by nutritional stress: implications for cancer gene therapy..  26:553-561. 2008
  • A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer..  26:286-295. 2008